Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arris acquires Sequana Therapeutics in a $166mm stock swap

Executive Summary

In a $166mm stock swap, drug discovery company Arris acquired genomics-based Sequana. Arris will issue Sequana stockholders 1.35 shares of its common stock for each Sequana share, or about $16.20 apiece, based on its own $12 trading price.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Full Acquisition
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register